The American Journal of Managed Care® (AJMC®) dicussed the efficacy of ragweed sublingual immunotherapy (SLIT) tablets with Anne Ellis, MD, professor of medicine and chair of the Division of Allergy & Immunology at Queen's University in Kingston, Ontario, Canada.
The American Journal of Managed Care® (AJMC®) dicussed the efficacy of ragweed sublingual immunotherapy (SLIT) tablets with Anne Ellis, MD, professor of medicine and chair of the Division of Allergy & Immunology at Queen's University in Kingston, Ontario, Canada. Ellis' study entitled, "Efficacy and Safety of Ragweed SLIT-Tablets Across Peak and Entire Season in Children with Allergic Rhinoconjunctivitis" found ragweed SLIT-tablets were efficacious in children with allergic rhinitis with or without conjunctivitis. The abstract was released through the American Academy of Allergy, Asthma & Immunology (AAAAI), which canceled its 2020 Annual Meeting due to COVID-19.
AJMC®: During peak season, daily symptom score and daily medication score were improved with ragweed SLIT tablets versus placebo in children. Did your study find any differences in efficacy of the treatment in children when compared to adults?
Ellis: Yes, actually, the treatment ended up being more effective in children than it was in the adult population when you compared the results of this trial back to the original Ragwitek trials that led to the Ragwitek tablet being approved for use in North America.
AJMC®: Why did you select ragweed as the allergen to test in this study?
Ellis: The Ragwitek tablet has already been approved for use in adults, and there was a desire to determine whether or not it would be efficacious in children as well. There's definitely desire both from the manufacturers of new products as well as the FDA to ensure that any new product that is approved in adults also has follow-on studies in the pediatric population to provide actual data in the pediatric population rather than just extrapolating from adult data before allowing it to be used in children.
AJMC®: Did you find in your study that the tablets had a greater effect on children with asthma?
Ellis: It's important to note a few distinctions there. The efficacy for reducing ragweed induced allergic rhinitis symptoms wasn't necessarily better just because you have asthma. But what was an unexpected and very pleasant and helpful finding was how much the tablet worked to improve asthma symptoms in children with ragweed allergy and allergic asthma. It's not that you do better from a rhinitis perspective because you have asthma, but your asthma actually improves.
AJMC®: Do you hope that reducing allergy symptoms in children with asthma via the tablets could reduce usage of asthma controller medications?
Ellis: Certainly reduction of asthma medications in general, that's what was shown in our study was that there was a much greater reduction in the use of rescue short-acting beta agonists in the patients treated with the tablet compared to those treated with placebo.
AJMC®: What are the real world implications of this study?
Ellis: The real world implications of this trial is that this tablet is highly efficacious in reducing symptoms of hay fever, or allergic rhinitis, in children with ragweed induced allergies, but also in reducing symptoms and rescue medication use for those children who also have asthma in addition to ragweed allergy.
AJMC®: Is there a timeline for these tablets coming to market or being approved?
Ellis: Personally, I'm in Canada, so our regulatory timelines are different from what is possibly anticipated in the United States. But I can tell you that this data has been submitted to both the FDA and Health Canada and approval is anticipated, but I can't give you an exact projection on the timeline at this point.
AJMC®: Is there anything that stood out about your research or do you have any points you'd like to highlight?
Ellis: I think it's important for anyone reading about the study to recognize just how very highly effective the treatment was in the pediatric population. It indicates that perhaps we should be thinking sooner about intervening with immunotherapies for children, rather than waiting until adulthood when the disease is more established and possibly harder to change the course. One of the advantages of these types of tablets is they can be given safer than traditional subcutaneous immunotherapy injections and therefore are more palatable and likely to be thought of in the pediatric population.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More